227. オスラー病 Osler disease Clinical trials / Disease details


臨床試験数 : 54 薬物数 : 73 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04139018
(ClinicalTrials.gov)
October 20, 201923/10/2019Timolol Gel for Epistaxis in Hereditary Hemorrhagic TelangiectasiaEfficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled TrialHereditary Hemorrhagic TelangiectasiaDrug: Timolol Gel;Drug: Placebo GelWashington University School of MedicineNULLRecruiting20 YearsN/AAll30Phase 2United States
2NCT02484716
(ClinicalTrials.gov)
June 201517/6/2015Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus PlaceboTelangiectasia, Hereditary Hemorrhagic;Osler Rendu DiseaseDrug: Timolol nasal spray;Drug: Placebo nasal sprayHospices Civils de LyonNULLCompleted18 YearsN/AAll58Phase 2France
3EUCTR2015-000385-55-FR
(EUCTR)
12/05/201529/03/2017Essai d’efficacité du timolol en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler.TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler.Essai randomisé en double insu contre placebo - TEMPO Rendu-Osler disease
MedDRA version: 19.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Timolol Alcon 0.5% collyre
Other descriptive name: TIMOLOL MALEATE
Hospices Civils de LyonNULLNot RecruitingFemale: yes
Male: yes
58Phase 2France
4NCT01752049
(ClinicalTrials.gov)
May 201314/12/2012Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of ConceptTopical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of ConceptHereditary Hemorrhagic TelangiectasiaDrug: Topical timolol maleate;Drug: placebo saline dropsUnity Health TorontoUniversity of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS)Completed18 YearsN/AAll5N/ACanada